VAP-1 in peritoneally dialyzed patients

Area of Science:

• Biochemistry
• Nephrology
• Cardiovascular Medicine

Background:

• Vascular adhesion protein-1 (VAP-1) exhibits semicarbazide-sensitive amine oxidase (SSAO) activity.
• Elevated serum VAP-1 is observed in hyperglycemia, diabetes, and chronic kidney disease.
• Renalase, involved in catecholamine breakdown, is expressed in the endothelium and kidneys.

Purpose of the Study:

• To determine serum VAP-1 levels in peritoneal dialysis (PD) patients.
• To identify factors influencing VAP-1 variability in PD patients.

Main Methods:

• Pilot study involving 25 PD patients (4 with type 2 diabetes) and a control group.
• Comparison of VAP-1 levels, catecholamines (dopamine, noradrenaline), and clinical parameters.
• Correlation analysis between VAP-1 and factors like residual renal function, glucose, and blood pressure.

Main Results:

• Mean VAP-1 was significantly higher in PD patients compared to controls.
• PD patients showed lower dopamine and higher noradrenaline levels than healthy volunteers.
• VAP-1 levels differed significantly based on residual renal function and glucose status (hyperglycemia vs. normoglycemia).
• VAP-1 correlated negatively with residual renal function and positively with glucose levels.

Conclusions:

• Serum VAP-1 is elevated in PD patients.
• VAP-1 levels are primarily influenced by residual kidney function and glucose levels.
• These factors are associated with endothelial damage and cardiovascular complications in PD patients.